Description

Retatrutide (LY‑3437943) is a novel triple receptor agonist in development by Eli Lilly, designed to target GLP‑1, GIP, and glucagon receptors simultaneously for enhanced weight loss, metabolic health, and appetite control Lilly Investor Relations+13The Care Pharmacy+13Peptide Sciences+13.

• Dose: 6 mg per weekly injection

• Purity: 99%, USA-made research-grade peptide

• Form: Lyophilized powder (vial) for reconstitution and subcutaneous injection

📈 Clinical Highlights

• Phase 2 trials demonstrated up to 17.5% weight loss at 24 weeks, and 24.2% at 48 weeks NowPatient+2GoodRx+2The Care Pharmacy+2Peptide Sciences+3Uk compounding+3Uk compounding+3Peptide SciencesThe Care Pharmacy+2Lilly Investor Relations+2NowPatient+2.

• Also shown to reduce HbA1c, liver fat, and improve lipid profiles GoodRx+2The Care Pharmacy+2NowPatient+2.